Evidence map›Paper›PMID 37658057›Full record

ArticleNature communications2023

Removal of false positives in metagenomics-based taxonomy profiling via targeting Type IIB restriction sites.

Zheng Sun, Jiang Liu, Meng Zhang, Tong Wang, Shi Huang, Scott T Weiss, Yang-Yu Liu

Abstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Detection ofFood chemistry. Molecular sciences · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zheng Sun *Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8537-8576
Jiang Liu *Qingdao OE Biotechnology Company Limited, Qingdao, Shandong, China.
Meng Zhang *Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, China.ORCID http://orcid.org/0000-0001-5841-4079
Tong WangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Shi HuangFaculty of Dentistry, The University of Hong Kong, Hong Kong, China.
Scott T WeissChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yang-Yu LiuChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. yyl@channing.harvard.edu.ORCID http://orcid.org/0000-0003-2728-4907

Funding

Multi-omic approaches to mechanisms of vitamin D, environmental influences, and the microbiome on asthmaUH3OD023268 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI LITONJUA, AUGUSTO A, WEISS, SCOTT T · 2018 to 2022
$13.5M
Functional Redundancy of Human Microbiome and its Implication in Fecal Microbiota TransplantationR01AI141529 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LIU, YANG-YU · 2019 to 2023
$4.5M
Revealing the role of blood microbiome in childhood asthmaK99HL163519 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SUN, ZHENG · 2023 to 2024
$346k
NHLBI NIH HHS K99 HL163519NIAID NIH HHS R01 AI141529NIH HHS UH3 OD023268
6 · The paper itself

Abstract

Accurate species identification and abundance estimation are critical for the interpretation of whole metagenome sequencing (WMS) data. Yet, existing metagenomic profilers suffer from false-positive identifications, which can account for more than 90% of total identified species. Here, by leveraging species-specific Type IIB restriction endonuclease digestion sites as reference instead of universal markers or whole microbial genomes, we present a metagenomic profiler, MAP2B (MetAgenomic Profiler based on type IIB restriction sites), to resolve those issues. We first illustrate the pitfalls of using relative abundance as the only feature in determining false positives. We then propose a feature set to distinguish false positives from true positives, and using simulated metagenomes from CAMI2, we establish a false-positive recognition model. By benchmarking the performance in metagenomic profiling using a simulation dataset with varying sequencing depth and species richness, we illustrate the superior performance of MAP2B over existing metagenomic profilers in species identification. We further test the performance of MAP2B using real WMS data from an ATCC mock community, confirming its superior precision against sequencing depth. Finally, by leveraging WMS data from an IBD cohort, we demonstrate the taxonomic features generated by MAP2B can better discriminate IBD and predict metabolomic profiles.

Indexed as

Inflammatory Bowel DiseasesMetagenomicsBase SequenceBenchmarkingComputer SimulationHumans

Identifiers

PMID37658057
PMCPMC10474111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.